Is Pfizer Stock (PFE) Worth Buying After Its Weight Loss Pill Failure?
Pfizer (PFE) stock was up on Monday despite the pharmaceutical company ending the clinical trial of its once-daily GLP-1 weight loss pill, danuglipron. The company had to cut this trial off early after one patient suffered liver damage. This is believed to have been caused by danuglipron, as the issue subsided once the person stopped taking the weight loss drug.
Stay Ahead of the Market:
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
That's a major blow to Pfizer as the company hoped to enter the GLP-1 weight loss race with danuglipron. It hoped the pill would compete against other weight loss drugs, such as Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Zepbound. Danuglipron could have offered a significant advantage over those two drugs as they require weekly injections compared to Pfizer's once-daily pill plan.
This marks the second time that danuglipron has failed Pfizer. The first time was when it discontinued a trial of patients taking the pill twice a day. It did so due to a high number of patient withdrawals over negative side effects, such as vomiting and nausea.
What's Next for Pfizer?
Pfizer has given up on the development of danuglipron after this latest failure. The company said it would no longer continue to research the molecule. Instead, PFE intends to continue research and development of its other weight loss drug candidates.
Despite today's failed clinical trial news, PFE stock was up 1.12% on Monday morning. Even so, the shares are still down 15.11% year-to-date.
Is PFE Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts' consensus rating for Pfizer is Moderate Buy, based on four Buy and 10 Hold ratings. With that comes an average price target of $28.67, representing a potential 29.64% upside for PFE stock. These ratings and price targets may change as analysts reevaluate Pfizer after its clinical trial failure.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a day ago
- Globe and Mail
Graft vs Host Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Graft vs Host Disease pipeline constitutes 45+ key companies continuously working towards developing 50+ Graft vs Host Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. ' Graft vs Host Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graft vs Host Disease Market. The Graft vs Host Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Graft vs Host Disease Pipeline Report: Companies across the globe are diligently working toward developing novel Graft vs Host Disease treatment therapies with a considerable amount of success over the years. Graft vs Host Disease companies working in the treatment market are Abbisko Therapeutics, Theriva Biologics, Seres Therapeutics, Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others, are developing therapies for the Graft vs Host Disease treatment Emerging Graft vs Host Disease therapies in the different phases of clinical trials are- ABSK021, SYN-004, SER-155, CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others are expected to have a significant impact on the Graft vs Host Disease market in the coming years. In April 2025, The California Institute for Regenerative Medicine (CIRM) has granted $8 million to biotech firm Tr1X to advance its Phase I/IIa clinical trial of TRX103. This therapy aims to prevent graft-versus-host disease (GvHD) in blood cancer patients receiving mismatched stem cell transplants. TRX103 is an allogeneic, engineered type 1 regulatory (Tr1) Treg cell therapy designed to reduce transplant-related complications and improve patient outcomes. In March 2025, Orca Bio's investigational T-cell immunotherapy for blood cancers significantly improved outcomes, more than doubling the rate of patients who remained free from moderate-to-severe chronic graft-versus-host disease (GvHD). According to results from the Phase III Precision-T trial (NCT05316701), 78% of patients treated with Orca-T (TRGFT-201), the company's lead allogeneic T-cell therapy, were GvHD-free after one year, compared to only 38% in the group receiving standard allogeneic stem cell transplants. In January 2025, MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech company specializing in Microbiome Ecosystem Therapies™ (MET) aimed at improving survival outcomes in cancer patients through immune system modulation, has announced positive topline results from its pivotal Phase 3 ARES trial. This single-arm, open-label, multicenter study conducted across Europe assessed the safety and efficacy of MaaT013 in patients with acute Graft-versus-Host Disease involving the gastrointestinal tract (GI-aGvHD) who are in third-line treatment — meaning they are resistant to steroids and either refractory or intolerant to ruxolitinib. The trial successfully achieved its primary endpoint, with a 28-day gastrointestinal overall response rate (GI-ORR) of 62%, significantly surpassing the expected rate of 38%. These outcomes, evaluated by an Independent Review Committee (IRC), exceeded the predefined efficacy threshold and underscore the strong clinical potential of MaaT013 in treating third-line GI-aGvHD. In December 2024, The FDA has granted approval to Mesoblast's allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, remestemcel-L, for treating steroid-refractory acute graft versus host disease (GvHD) in pediatric patients aged two months and older. Significantly, this marks the first FDA-approved MSC-based therapy. The treatment will be commercially available under the brand name Ryoncil. Graft vs Host Disease Overview Graft versus Host Disease (GvHD) is a medical condition that can occur after a stem cell or bone marrow transplant, where the donor's immune cells (graft) recognize the recipient's body (host) as foreign and attack it. GvHD commonly affects the skin, liver, and gastrointestinal tract. It is classified into acute and chronic forms, with symptoms ranging from mild rashes and diarrhea to severe organ damage. Management typically involves immunosuppressive therapies to reduce the immune response. Emerging Graft vs Host Disease Drugs Under Different Phases of Clinical Development Include: ABSK021: Abbisko Therapeutics SYN-004: Theriva Biologics SER-155: Seres Therapeutics CB103: Cellestia Biotech Glasdegib: Pfizer TQ 05105: Chia Tai Tianqing Pharmaceutical RGI-2001: Regimmune Corporation Axatilimab: Syndax Pharmaceuticals MaaT013: MaaT Pharma MC 0518: Medac Itolizumab: Equillium Elranatamab: Pfizer Felzartamab: Janssen Pharmaceutical T-Guard: Xenikos MaaT013: MaaT Pharma Axatilimab: Syndax Pharmaceuticals TQ 05105: Chia Tai Tianqing Pharmaceutical Group Graft vs Host Disease Route of Administration Graft vs Host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Oral Intravenous Subcutaneous Graft vs Host Disease Molecule Type Graft vs Host Disease Products have been categorized under various Molecule types, such as Small molecule Cell Therapy Peptides Polymer Small molecule Gene therapy Graft vs Host Disease Pipeline Therapeutics Assessment Graft vs Host Disease Assessment by Product Type Graft vs Host Disease By Stage and Product Type Graft vs Host Disease Assessment by Route of Administration Graft vs Host Disease By Stage and Route of Administration Graft vs Host Disease Assessment by Molecule Type Graft vs Host Disease by Stage and Molecule Type DelveInsight's Graft vs Host Disease Report covers around 50+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Graft vs Host Disease product details are provided in the report. Download the Graft vs Host Disease pipeline report to learn more about the emerging Graft vs Host Disease therapies Some of the key companies in the Graft vs Host Disease Therapeutics Market include: Key companies developing therapies for Graft vs Host Disease are - Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Medsenic, Xenothera, Xenikos, AltruBio Inc., Biogen, OncoImmune, Inc., Cellect Biotechnology, AstraZeneca, Bristol-Myers Squibb, Dystrogen Therapeutics, CTI BioPharma, Ossium Health, Inc., Orca Biosystems, Inc., Synthetic Biologics Inc., Cellenkos, Corvus Pharmaceuticals, ImStem Biotechnology, Rheos Medicines, Equillium, Cellestia Biotech, Genentech, Humanigen, CSL Behring, ADIENNE, and others. Graft vs Host Disease Pipeline Analysis: The Graft vs Host Disease pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Graft vs Host Disease with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graft vs Host Disease Treatment. Graft vs Host Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Graft vs Host Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graft vs Host Disease market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Graft vs Host Disease Pipeline Market Drivers Increase in the number of patients suffering from chronic GvHD, robust Pipeline of GvHD are some of the important factors that are fueling the Graft vs Host Disease Market. Graft vs Host Disease Pipeline Market Barriers However, high cost of treatment, recognizing the limitations of currently available aGVHD therapies and other factors are creating obstacles in the Graft vs Host Disease Market growth. Scope of Graft vs Host Disease Pipeline Drug Insight Coverage: Global Key Graft vs Host Disease Companies: Abbisko Therapeutics, Theriva Biologics, Seres Therapeutics, Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others Key Graft vs Host Disease Therapies: ABSK021, SYN-004, SER-155, CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others Graft vs Host Disease Therapeutic Assessment: Graft vs Host Disease current marketed and Graft vs Host Disease emerging therapies Graft vs Host Disease Market Dynamics: Graft vs Host Disease market drivers and Graft vs Host Disease market barriers Table of Contents 1. Graft vs Host Disease Report Introduction 2. Graft vs Host Disease Executive Summary 3. Graft vs Host Disease Overview 4. Graft vs Host Disease- Analytical Perspective In-depth Commercial Assessment 5. Graft vs Host Disease Pipeline Therapeutics 6. Graft vs Host Disease Late Stage Products (Phase II/III) 7. Graft vs Host Disease Mid Stage Products (Phase II) 8. Graft vs Host Disease Early Stage Products (Phase I) 9. Graft vs Host Disease Preclinical Stage Products 10. Graft vs Host Disease Therapeutics Assessment 11. Graft vs Host Disease Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Graft vs Host Disease Key Companies 14. Graft vs Host Disease Key Products 15. Graft vs Host Disease Unmet Needs 16 . Graft vs Host Disease Market Drivers and Barriers 17. Graft vs Host Disease Future Perspectives and Conclusion 18. Graft vs Host Disease Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
a day ago
- Globe and Mail
Tesla Stock Poised to Maintain ‘Upward Momentum,' Says Top Analyst
Alexander Potter believes that Tesla (TSLA) stock 'will likely sustain its upward momentum over the coming weeks' in his latest research note. The five-star analyst maintained his 'Buy' rating and $400 price target, which implies 22.5% upside potential from current levels. Potter ranks #444 out of the 9,636 analysts ranked on TipRanks. He boasts an average return per rating of 18.6% and a success rate of 48%. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Tesla stock has lost 19.2% year-to-date due to multiple issues. The electric vehicle (EV) maker has been facing some of its most ruthless trading weeks, marked by diminishing global auto deliveries, backlash against CEO Elon Musk 's political choices, and the most recent public showdown between Musk and President Donald Trump. Robotaxi Event Could Be a Make-or-Break for TSLA Potter highlighted that the firm's 'key component' of Tesla's robotaxi launch has started to play out. Tesla's autonomous robotaxis have been seen on the streets of Austin, Texas, and Musk has confirmed the deployment of the company's driverless taxis in the city. Having said that, the analyst warns that any high-profile robotaxi accident could likely trigger a 'violent downside' move in the stock price. A majority of analysts have assigned a premium valuation to Tesla's future price targets due to the highly anticipated robotaxi service. Both investors and analysts are excited about Tesla's foray into the full self-driving (FSD) technology. On June 10, Musk posted a video on X that showed Tesla's driverless taxis running on Austin's streets. At the same time, Musk revealed that the commercial launch date for the robotaxis would be June 22. Meanwhile, he also mentioned that Tesla is targeting to deliver its first-ever FSD vehicle to a customer's home by June 28. This vehicle, he said, will drive itself from the end of the factory line directly to a customer's home. Expectations are running high for Tesla's autonomous vehicle initiatives, while the company and its CEO remain highly cautious. 'We are being super paranoid about safety, so the date could shift,' Musk wrote on X on Tuesday. Following its success in Austin, Tesla aims to roll out the robotaxi service to other cities. Is it a Good Idea to Buy Tesla Stock? Analysts remain cautious about Tesla's long-term stock trajectory owing to various challenges. However, the rift between Musk and Trump seems to have eased, with the former backtracking on his rather critical comments about the President. Meanwhile, the President has also confirmed that he would not be canceling SpaceX's contracts, nor will he sell the Tesla Model S he recently bought, nor stop using Starlink's satellite service at the White House. For now, all eyes are on Tesla's robotaxi event scheduled for next week. On TipRanks, TSLA stock has a Hold consensus rating based on 14 Buys, 12 Holds, and nine Sell ratings. Also, the average Tesla price target of $285.97 implies 12.4% downside potential from current levels. See more TSLA analyst ratings
Globe and Mail
2 days ago
- Globe and Mail
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds
With the end of the pandemic, sales of Pfizer 's PFE COVID products, Comirnaty and Paxlovid, have declined. Though COVID revenues are declining, Pfizer's non-COVID operational revenues improved in 2024 and so far in 2025, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen. Year 2023 was a record year for Pfizer in terms of new drug approvals. It received nine new medicine/vaccine approvals in 2023 that have begun to contribute to top-line growth. In 2024, it gained approval for some interesting new products like two gene therapies for hemophilia, Hympavzi (marstacimab) and Beqvez/Durveqtix (fidanacogene elaparvovec). The December 2023 acquisition of Seagen strengthened Pfizer's position in oncology by adding four antibody-drug conjugates or ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer's revenues in 2024 and the first quarter of 2025. Seagen also has some next-generation ADC candidates in its pipeline. Pfizer faces its share of challenges, including declining sales of its COVID-19 products, U.S. Medicare Part D headwinds, the upcoming loss of exclusivity cliff, uncertainties around tariffs and a volatile macro environment. However, its new products/late-stage pipeline candidates and newly acquired products, including those acquired from Seagen, position it strongly for operational growth in 2025 and beyond. Competition in the Oncology Space Other large players in the oncology space are AstraZeneca AZN, Merck MRK and Bristol-Myers BMY. For AstraZeneca, oncology sales now comprise around 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca's strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). Merck's key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Bristol-Myers' key cancer drug is PD-LI inhibitor, Opdivo, which accounts for around 20% of its total revenues. PFE's Price Performance, Valuation and Estimates Pfizer's stock has declined 4.4% so far this year compared with an increase of 3.1% for the industry. Image Source: Zacks Investment Research From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 7.97 forward earnings, lower than 15.54 for the industry and the stock's 5-year mean of 10.91. The Zacks Consensus Estimate for 2025 earnings has risen from $2.98 per share to $3.06 per share, while that for 2026 has gone up from $3.00 to $3.09 per share over the past 60 days. Pfizer has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
